

Form PTO-1449	Attorney's Docket No. 39780-1618P2C46	Application Serial No. 09/903,520
INFORMATION DISCLOSURE STATEMENT		Applicant(s) ASHKENAZI, et al.
Filing Date: July 11, 2001		Group Art Unit: 1646

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
N/K	1.	8/21/90	4,950,647	Robins et al.			10/4/88
	2.	7/15/97	5,648,376	Strobel et al.			1/19/95
	3.	9/1/98	5,801,193	Ojo-Amaize et al.			4/15/97
	4.	10/6/98	5,817,306	Haskill et al.			6/7/95
	5.	09/28/99	5,958,403	Storm, et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation
							YES NO

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
N/K	6.	Abolhassani, M., "Antibacterial effect of borage (<i>Echium amoenum</i>) on <i>Staphylococcus aureus</i> ," <i>Brazilian Journal of Infectious Diseases</i> 8:382-385 (2004).
	7.	Amirghofran, Z. et al., "Echium amoenum stimulate of lymphocyte proliferation and inhibit fo humoral antibody synthesis," <i>Im. J. Med. Sci.</i> 25:119-124 (2000).
	8.	Chapoval, A. I. et al., "Combination chemotherapy and IL-15 administration induces permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells," <i>J. Immunol.</i> 161:6977-6984 (1998).
	9.	Fung-Leung, et al., "Tepoxallin, A Novel Immunomodulatory Compound, Synergizes with CSA in Suppression of Graft-Versus-Host Reaction and Allogeneic Skin Graft Rejection", <i>Transplantation</i> , 60:362-368 (1995).
	10.	Gennari, R. et al., "Granulocyte macrophage colony-stimulating factor improves survival in two models of gut-derived sepsis by improving gut barrier function and modulating bacterial clearance," <i>Annals of Surgery</i> 220:68-76 (1994).
	11.	Grabstein, K.H. et al., "Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor," <i>Science</i> 264:965-968 (1994)
	12.	Kasaian, M.T. et al., "IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity," <i>Immunity</i> 16:559-569 (2002).
	13.	Kirchner, G.I. et al., "Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application," <i>Br. J. Clin. Pharmacol.</i> 46:5-10 (1998).
	14.	Ma, H-L et al., "IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of INF- γ ," <i>J. Immunol.</i> 171:608-615 (2003).
	15.	Naito, K. et al., "Macrophage factors which enhance the mixed leukocyte reaction initiated by dendritic cells," <i>J. Immunol.</i> 142:1834-1839 (1989).
	16.	Nastala, C.L. et al., "Recombinant IL-12 administration induces tumor regression in association with IFN- γ production," <i>J. Immunol.</i> 153:1697-1706 (1994).
	17.	Pahwa, R. et al. "Recombinant interleukin 2 therapy in severe combined immunodeficiency disease," <i>Proc. Natl. Acad. Sci. USA</i> 86:5069-5073 (1989).
	18.	Patterson, S. et al., "Human invariant NKT cells are required for effective in vitro alloresponses," <i>J. Immunol.</i> 175:5087-5094 (2005).

EXAMINER: N/K	DATE CONSIDERED: 1/17/07
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	

[illegible]

EXAMINER: <i>N. Smith</i>	DATE CONSIDERED: <i>11/17/07</i>
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	

SV 2242374 v1